UPDATE: Brean Capital Assumes Alexion Pharmaceuticals (ALXN) at Buy

October 4, 2016 9:07 AM EDT
Get Alerts ALXN Hot Sheet
Price: $132.07 +4.82%

Rating Summary:
    21 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ALXN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - October 4, 2016 10:10 AM EDT)

Brean Capital assumed coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Buy rating and a price target of $221.

Analyst Jason Wittes said, "We are maintaining estimates, which assume continued growth in Soliris (a terminal complement inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)), and strong uptake of recently launched Strensiq (an enzyme replacement therapy for perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)) and Kanuma (an enzyme therapy approved for the treatment of patients with lysosomal acid lipase deficiency (LAL-D)). The company also has diversified itself with a robust rare disease pipeline, with six new products/indication potential approvals by 2018."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $122.14 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Brean Capital

Add Your Comment